CAREstream America has announced an exclusive distribution partnership that introduces Celltermi HS and NX Plus to the United States aesthetic market, marking a significant development in science-driven skin and hair care solutions. The agreement strengthens the company’s position in the growing aesthetics sector while expanding access to advanced microbiome-based technologies for qualified providers nationwide.
The launch focuses on Celltermi HS & NX Plus, which is a probiotic-based microbiome technology aimed at assisting aesthetics professionals in sourcing scientifically proven topical products. These innovative products integrate patented ingredients and biomaterial research, leading to the creation of a brand-new category of scientifically backed products for skincare and haircare applications.
CAREstream America, known for distributing medical and aesthetic technologies, stated that the partnership reflects increasing demand for products supported by research, manufacturing integrity, and transparent development processes. As the aesthetic industry continues evolving, providers are placing greater emphasis on quality assurance and clinical credibility when selecting products for their practices.
CHA Meditech, a subsidiary of CHA Bio Group, developed Celltermi HS and NX Plus with patented biomaterial technologies and extensive research expertise. CHA Bio Group has over six decades of experience in regenerative medicine, biomaterials, and healthcare innovation. The partnership leverages existing scientific expertise, as well as CAREstream America’s distribution network and market reach.
The partnership is about raising the standard in the aesthetic market, said company executives. They noted that practitioners are increasingly looking for reliable products based on sound scientific principles rather than marketing claims. The launch of Celltermi HS and NX Plus is therefore in line with the industry-wide push to focus on evidence-based innovation.
The newly launched solutions were designed with a focus on ingredient quality, manufacturing consistency, and scientific validation. Unlike many products competing within the same category, Celltermi HS and NX Plus were developed using proprietary components supported by an established South Korean biomaterials organization. As a result, the companies believe the products offer enhanced credibility in a rapidly expanding marketplace.
Industry observers have highlighted growing interest in microbiome-focused technologies as aesthetic providers search for differentiated treatment options. Meanwhile, advancements in regenerative science continue influencing product development strategies across both medical and cosmetic sectors. In this environment, Celltermi HS and NX Plus enter the market with an emphasis on microbiome innovation and science-backed formulation.
This partnership also reflects a broader trend towards international collaborations in the field of aesthetics. It seeks to exploit research and development expertise in South Korea, combined with the distribution strengths of U.S. firms, thus enabling faster integration of innovative technologies by aesthetic practitioners. In addition, the alliance showcases the globalization of innovation in the healthcare and beauty sectors.
CAREstream America indicated that Celltermi HS and NX Plus are available immediately for qualified providers and practices throughout the United States. This immediate availability is expected to support aesthetic clinics seeking new offerings that emphasize transparency, scientific research, and product quality. Additionally, the launch expands the company’s portfolio of advanced solutions designed for modern healthcare and aesthetic environments.
Executives from both organizations described the partnership as a major milestone for the future of aesthetics. They claimed the combination of a strong scientific heritage and a strong commercial infrastructure offered opportunities to increase the confidence of professionals and the satisfaction of patients. The Celltermi HS and NX Plus thus represent a wider effort to set new standards of quality and innovation in the U.S. aesthetic industry.
As competition increases in the aesthetics market, providers continue to search for products that provide measurable value and scientific credibility. Hence, the launch of Celltermi HS and NX Plus could be an important step in this direction, as it supports the industry's move to research-driven solutions to meet those expectations. With immediate market availability and strong backing from both companies, the products are expected to attract attention from aesthetic professionals across the country.
